Form 4: Inhibikase Therapeutics CFO Garth Lees-Rolfe Reports Option Repricing

Garth Lees-Rolfe, CFO of Inhibikase Therapeutics, reports repricing of stock options effective January 21, 2025.

Summary

• Garth Lees-Rolfe, the Chief Financial Officer of Inhibikase Therapeutics, Inc., filed a Form 4 on January 22, 2025, reporting changes in beneficial ownership.
• The reported transactions involve the repricing of stock options, which was approved by the Issuer's Board of Directors on October 9, 2024, and the Issuer's stockholders on January 3, 2025.
• The repricing became effective on January 21, 2025.
• The CFO was granted 5,834 options at $1.26 and 90,000 options at $1.26.
• The CFO had 5,834 options at $3.79 and 90,000 options at $2.16 which were disposed of.
• The options are exercisable and expire on November 28, 2029, and April 1, 2031, respectively.
• The underlying security for these options is common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. Option repricing can be seen as a positive sign of incentivizing management, but it also suggests the original option grants may have been underwater due to stock performance.

Positives

• The option repricing suggests an effort to incentivize the CFO, potentially aligning his interests with those of the shareholders.

Industry Context

Option repricing is a common practice in the biotech industry to retain and incentivize key executives, especially when the company's stock price has underperformed.

Stakeholder Impact

• Shareholders may view the option repricing as a positive move to align management's interests with the company's performance.
• Employees may see this as a sign of the company's commitment to retaining key personnel.

Key Dates